Related by context. All words. (Click for frequent words.) 74 tolerability 74 efficacy tolerability 71 analgesic efficacy 69 tolerability profile 67 effectiveness 67 pharmacokinetics PK 66 Efficacy 66 immunogenicity 66 antiviral efficacy 66 pharmacodynamics PD 66 viral kinetics 66 pharmacokinetic profile 66 antiviral activity 65 preclinical efficacy 65 pharmacodynamic properties 65 pharmacokinetic profiles 64 pharmacokinetic 64 antitumor activity 64 pharmacokinetics 64 pharmacodynamic profile 63 pharmacokinetic properties 63 antitumor effect 63 pharmacokinetic parameters 62 LEP ETU 62 active comparator 62 efficacy endpoints 62 clinical trial 62 bioavailability 62 Hyphanox 62 therapeutic equivalence 62 NP2 Enkephalin 62 randomized controlled clinical trials 62 preclinically 62 clinical trials 62 pharmacodynamic effects 61 tolerability profiles 61 pharmacodynamic PD 61 tipranavir 61 dosing regimens 61 SCH # 61 vidofludimus 61 AZILECT R 61 placebo controlled trials 61 noninferiority 61 riociguat 61 pharmacokinetic characteristics 61 pharmacodynamic 61 placebo controlled studies 61 KRN# 61 antidepressant efficacy 61 cardioprotective effects 61 cannabinor 61 optimal dosing 61 safety tolerability pharmacokinetic 60 maximally tolerated dose 60 pharmacodynamics 60 antitumor efficacy 60 teriflunomide 60 ORMD 60 bioequivalence 60 Zoraxel 60 efficacious 60 Phase 2b study 60 systemic absorption 60 pain palliation 60 tanespimycin 60 clinical endpoints 60 tolerability pharmacokinetics 60 pharmacokinetic PK 60 CoFactor 60 RE SURGE 60 nab paclitaxel 60 safety tolerability pharmacokinetics 60 favorable pharmacokinetic profile 60 phase Ib 59 EFAPROXYN 59 antithrombotic 59 AZILECT ® 59 ADAGIO study 59 preclinical studies 59 pharmacokinetic PK study 59 antiviral potency 59 efficacies 59 CANCIDAS 59 RoACTEMRA 59 MAGE A3 ASCI 59 randomized clinical trials 59 anti leukemic 59 Protelos 59 trastuzumab DM1 59 oral bioavailability 59 urate lowering 59 monotherapy 59 Onbrez Breezhaler 59 torezolid phosphate 59 oral diclofenac 59 non inferiority 59 JAK inhibitor 59 Afatinib 59 phase IIb clinical 59 combinability 59 vivo efficacy 59 MAP# 59 pharmacokinetic equivalence 59 Traficet EN 59 mapatumumab 59 oral rivaroxaban 59 Phase 2a trial 59 tecarfarin 59 bicifadine 59 nebulized formoterol fumarate 59 biodistribution 59 Multimeric 59 placebo controlled 59 non selective NSAIDs 59 Phase 1b clinical 59 favorable tolerability 59 phase IIa 59 pharmacokinetics pharmacodynamics 59 viral kinetic 59 randomized trials 58 Androxal TM 58 Phase 1b trial 58 LDL lowering 58 tolerated dose MTD 58 gemifloxacin 58 intravenous cyclophosphamide 58 pharmacodynamic profiles 58 Phase Ib clinical 58 eltrombopag 58 Capesaris 58 oral prodrug 58 pharmacokinetic studies 58 safety tolerability 58 anticancer activity 58 Tarceva TM 58 dose proportionality 58 antitumor effects 58 PEGylated interferon beta 1a 58 neratinib 58 mertansine 58 ascending dose 58 secondary efficacy endpoints 58 nonclinical studies 58 FM VP4 58 placebo controlled clinical 58 Serdaxin 58 QLT# 58 phase IIa clinical 58 INCB# [001] 58 plasma pharmacokinetics 58 Targretin 58 PRT# 58 dose regimens 58 Phase IIa trial 58 teduglutide 58 subcutaneously administered 58 sorafenib Nexavar 58 DexaSite 58 dose escalation trial 58 trials RCTs 58 Octreolin 58 DermaVir Patch 58 Tolerability 58 indibulin 58 adipiplon 58 LT NS# 58 APTIVUS 58 CaPre TM 58 prucalopride 58 Phase 2a clinical 57 ganetespib 57 fosbretabulin 57 oral Xeloda 57 tiotropium 57 neuroprotective properties 57 rHuPH# 57 SPIRIVA HandiHaler 57 phase IIIb 57 AzaSite Plus 57 iniparib 57 RE LY ® 57 HCV protease inhibitors 57 RSD# oral 57 OncoVEX GM CSF 57 CRx 57 MGCD# [002] 57 efficacy endpoint 57 TNF alpha inhibitor 57 ancrod 57 TOLAMBA 57 subcutaneous formulation 57 ganaxolone 57 pertuzumab 57 dosage regimens 57 KRAS status 57 GLYX 57 adalimumab 57 paclitaxel poliglumex 57 PXD# 57 pharmacologic 57 edoxaban 57 Dual Opioid 57 antiplatelet agent 57 PSN# [002] 57 pharmacodynamic markers 57 MoxDuo TM IR 57 orBec 57 virologic response 57 CYT# 57 immunological responses 57 davunetide intranasal AL 57 dosing frequency 57 NATRECOR ® 57 salmeterol fluticasone 57 sulodexide 57 antiresorptive 57 cardiac toxicity 57 intravenous dosing 57 Phase #b/#a trial 57 CG# [003] 57 everolimus eluting stents 57 pharmacokinetic pharmacodynamic 57 confirmatory clinical 57 varespladib 57 Q#IR 57 coadministration 57 mg dose 57 potency selectivity 57 Phase IIa clinical 57 BAL# [002] 57 Menerba 57 delafloxacin 57 randomized controlled 57 Cethromycin 57 ToGA 57 pharmacokinetic interactions 57 TELINTRA 57 randomized clinical 57 velafermin 57 reslizumab 57 goserelin 57 casopitant 57 immunomodulator 57 pharmacokinetic PK profile 57 statistically significant superiority 57 LEVAQUIN ® 57 Inhalation Solution 57 Diamyd r vaccine 57 protease inhibitor PI 57 TELCYTA 57 surrogate endpoint 57 deferiprone 57 Ophena TM 57 oral FTY# 57 CRMD# 57 MoxDuo IR 57 antipsychotic efficacy 57 oral deforolimus 57 cangrelor 57 ACTEMRA TM 57 posaconazole 57 pomalidomide 57 Phase Ib 57 melphalan prednisone 56 temsirolimus 56 prospective randomized controlled 56 ADVANCE PD 56 forodesine 56 Vilazodone 56 reactogenicity 56 placebo controlled clinical trials 56 apremilast 56 mycophenolate mofetil 56 Phase Ib II 56 carboplatin paclitaxel 56 randomized multicenter Phase III 56 Zenvia 56 Phase IIb 56 Azedra 56 PURE proprietary 56 MoxDuo 56 DASISION 56 DAVANAT 56 tolevamer 56 Dalbavancin 56 HuMax EGFr 56 ritonavir boosted 56 afatinib 56 peginterferon alfa 2b 56 LibiGel ® 56 dual antiplatelet 56 erythropoietic 56 S/GSK# 56 pegylated liposomal doxorubicin 56 elagolix 56 tezampanel 56 phase IIb III 56 cediranib 56 Pharmacokinetic 56 PREOS 56 CBLC# 56 Phase Ib study 56 clevidipine 56 CIMZIA ™ 56 pharmacodynamic parameters 56 TLK# 56 ALGRX 56 decitabine 56 visilizumab 56 Preclinical studies 56 alvimopan 56 Rasilez Tekturna 56 CIMZIA TM certolizumab pegol 56 AEGR 56 multicentre randomized 56 randomized controlled clinical 56 Triapine R 56 multicenter randomized placebo controlled 56 phase IIb 56 budesonide foam 56 pramlintide metreleptin combination 56 idraparinux 56 inhaled iloprost 56 FTY# 56 mcg dose 56 UPLYSO 56 Phase IIIb clinical 56 PPAR gamma agonists 56 TAXUS VI 56 HspE7 56 GFT# 56 Phase IIa 56 Alpharadin 56 Zemplar Capsules 56 INC# 56 telbivudine 56 randomized multicenter 56 icatibant 56 zoledronate 56 subcutaneous SC 56 Phase Ia 56 BRAF inhibitor 56 pharmacoeconomic 56 phase 2a 56 orally inhaled migraine 56 docetaxel Taxotere 56 amrubicin 56 incyclinide 56 balsalazide tablet 56 CLORETAZINE TM VNP#M 56 ORENCIA ® 56 EmbraceAC 56 PDE4 inhibitors 56 MICARDIS ® 56 Perforomist ™ Inhalation Solution 56 Combo Stent 56 Tyrima 56 REMINYL ® 56 Tolvaptan 56 CCX# 56 antiplatelet 56 ruxolitinib 56 XL# SAR# 56 interferon gamma 1b 56 lapatinib Tykerb 56 Intravail R 56 Panzem R NCD 56 aripiprazole Abilify 56 endoscopic gastric ulcers 56 pitavastatin 56 gastrointestinal absorption 56 galiximab 56 Zybrestat 56 Bezielle 56 cethromycin 56 approvability 56 ILLUMINATE 56 MoxDuo ® IR 56 Phase IIb clinical 56 Spiriva HandiHaler 55 lacosamide 55 Cimzia TM 55 RE COVER 55 Non inferiority 55 ibandronate 55 mg kg BID 55 bevacizumab Avastin 55 Empatic 55 indacaterol 55 beclomethasone dipropionate 55 orally dosed 55 postmarketing surveillance 55 Exelixis compounds 55 randomized placebo controlled 55 iSONEP 55 CIMZIA TM 55 USL# 55 Interferon alpha 55 Onconase 55 Doxil ® 55 Pharmacokinetic studies 55 Phase #b/#a 55 toxicity 55 hemostatic efficacy 55 eluting stent 55 dosing 55 Avastin bevacizumab 55 randomized controlled trials 55 systemically administered 55 OMP #M# 55 retapamulin 55 nonrandomized 55 Visipaque 55 arzoxifene 55 Preclinical studies suggest 55 glatiramer acetate 55 Fodosine 55 AAG geldanamycin analog 55 IMGN# 55 obatoclax 55 pharmacodynamic endpoints 55 PROMACTA 55 randomized multicenter trial 55 irinotecan chemotherapy 55 antiangiogenic agents 55 ZYBRESTAT fosbretabulin 55 Phase III trials 55 tocilizumab 55 diabetic neuropathic pain 55 INVEGA SUSTENNA 55 platelet inhibitor 55 interferon alfa 2b 55 Phase IIB 55 dosage regimen 55 RE LY trial 55 alemtuzumab MS 55 BrachySil 55 aclidinium 55 vivo potency 55 liposomal formulation 55 EXPAREL ™ 55 ataluren 55 successfully commercialize Iluvien 55 NeuroSTAT ® 55 bosentan 55 LC#m# 55 Cancidas 55 peg interferon 55 clinically meaningful efficacy 55 rifalazil 55 Pharmacokinetic PK 55 glatiramer 55 TBC# 55 anidulafungin 55 PIX# [002] 55 ARCOXIA 55 dabigatran etexilate 55 low dose ritonavir 55 lanthanum carbonate 55 cobicistat 55 mometasone 55 iclaprim 55 Altastaph 55 Ophena 55 elacytarabine 55 investigational compound 55 Phase 1b 55 renal toxicity 55 HuMax CD# 55 Xinlay 55 Pemetrexed 55 sipuleucel T 55 cobiprostone 55 vitro studies 55 Phase III clinical 55 uric acid lowering 55 metastatic RCC 55 NGX# 55 TriRima 55 investigational 55 Valdoxan 55 LCP Tacro 55 lintuzumab 55 platelet inhibition 55 bronchodilation 55 isavuconazole 55 Carfilzomib 55 OPAXIO 55 BNC# 55 romidepsin 55 Cloretazine 55 systemic immunosuppressive drugs 55 Duromist ™ 55 Dabigatran etexilate 55 HGS# 55 docetaxel Taxotere ® 55 Elocalcitol 55 Synavive 55 antifibrotic 55 inhibitor RG# 55 Prosaptide 55 MEK inhibitors 55 OXi# 55 zalutumumab 55 lisdexamfetamine dimesylate 55 Chemophase 55 tasimelteon 55 #mg dose [001] 55 ENMD # 55 dexpramipexole 55 Plenaxis TM 55 PRECISE 55 GLP toxicology studies 55 SILENOR 55 EVIZON 55 canakinumab 55 tremelimumab 55 fluticasone furoate 55 CYPHER R Sirolimus eluting 55 PrevOnco ™ 55 TG# [003] 55 vorinostat 55 HGS ETR1 55 EOquin TM 55 DU #b 55 vaginal microbicide 55 zafirlukast 55 HCV SPRINT 55 PKC# 55 custirsen 55 MiStent DES 55 mecamylamine 55 L PPDS 55 oral ridaforolimus 55 Xanafide 55 tigecycline 55 histone deacetylase inhibitor 55 ProSavin 55 Amrubicin 55 Pazopanib 55 rNAPc2 55 antiarrhythmic 55 AZILECT 55 Fulvestrant 55 rilonacept 55 tapentadol ER 54 nesiritide 54 alvespimycin 54 lucinactant 54 subgroup analyzes 54 enoximone 54 SNRI 54 clinically meaningful 54 novel histone deacetylase 54 OHR/AVR# 54 CINTREDEKIN BESUDOTOX 54 Bicifadine 54 lubiprostone 54 DAPT 54 erlotinib Tarceva ® 54 etanercept Enbrel 54 Valortim ® 54 randomized blinded 54 prulifloxacin 54 clinically relevant 54 aflibercept 54 Factor Xa inhibitor 54 Aplidin 54 alicaforsen enema 54 MGN# 54 teriparatide 54 adjunctive 54 ASCEND HF 54 lasofoxifene 54 Tekamlo 54 adecatumumab 54 radiographic outcomes 54 fondaparinux 54 ELACYT 54 rt PA 54 Phase IIIb 54 CRLX# 54 Alequel ™ 54 Phase IIb clinical trials 54 Cloretazine R VNP#M 54 ISIS # 54 Zenvia ™ 54 CA4P 54 HuLuc# 54 OvaRex R 54 eprotirome 54 GRN#L 54 phase IIb trial 54 bioactivity 54 randomized Phase III 54 divalproex sodium 54 ANAVEX #-# [001] 54 paclitaxel Taxol 54 achieved statistical significance 54 SinuNase TM 54 FOLPI 54 Archexin 54 dose cohort 54 Apoptone 54 Rivaroxaban 54 Gefitinib 54 MBP# [001] 54 clomipramine 54 immune modulating 54 enzastaurin 54 micafungin 54 administered subcutaneously 54 Kinoid 54 IMA# 54 polymerase inhibitor 54 YONDELIS 54 PEG SN# 54 GAMMAGARD 54 selective modulator 54 certolizumab 54 inecalcitol 54 HGS ETR2 54 Ketotransdel 54 antiplatelet therapies 54 colesevelam HCl 54 mg QD 54 M6G 54 Imprime PGG 54 HZT 54 Phase 1a clinical 54 dose cohorts 54 Lorqess 54 ROCKET AF 54 LCP AtorFen 54 LE DT 54 Histalean TM 54 dalbavancin 54 AVANDIA 54 Golimumab 54 OMS#HP 54 antithrombotics 54 Aptivus 54 darunavir r 54 TAXUS Stent 54 EndoTAG TM -1 54 double blinded randomized 54 equi analgesic doses 54 pegylated interferon alfa 2b 54 TMC# C# 54 antiandrogens 54 desvenlafaxine succinate 54 PREZISTA r 54 antiangiogenic activity 54 efavirenz EFV 54 double blinded placebo 54 intravesical instillation 54 lurasidone 54 Adlea 54 Taxotere chemotherapy 54 AVERROES 54 HyQ 54 NEVO ™ 54 Phase Ib clinical trials 54 multicenter trials 54 Novo Nordisk Victoza 54 GnRH antagonist 54 glucose lowering 54 febuxostat 54 celgosivir 54 investigational drug 54 orally bioavailable 54 talactoferrin 54 SinuNase 54 APTIVUS r 54 optimal dosing regimen 54 bioequivalency 54 systemic RNAi therapeutic 54 Spiegelmer ® 54 systemic bioavailability 54 cetuximab Erbitux ® 54 picoplatin 54 vinorelbine 54 #D#C# 54 Dapagliflozin 54 Pharmacokinetics PK 54 receptor inhibitor 54 CTAP# Capsules 54 demonstrated antitumor activity 54 ixabepilone 54 TH# [003] 54 lenalidomide dexamethasone 54 Tracleer R 54 Pimavanserin 54 Vaxfectin TM adjuvant 54 cytotoxicity 54 VIAject R 54 PEGPH# 54 NEVO TM 54 Isolagen Therapy 54 AChE inhibitors 54 Virulizin ® 54 oral anticancer 54 CR# vcMMAE 54 serotonin norepinephrine reuptake inhibitor 54 preclinical pharmacokinetic 54 Anidulafungin 54 relapsing multiple sclerosis 54 TRANSFORMS 54 Phase 2b trial 54 Pennsaid R 54 telcagepant 54 nitazoxanide 54 latanoprost 54 trodusquemine 54 Allovectin 7 ® 54 thymalfasin 54 Vidaza azacitidine 54 ZYBRESTAT 54 investigational protease inhibitor 54 HIF PH inhibitors 54 AQ4N 54 APPRAISE 54 axitinib 54 zonisamide SR 54 multidose 54 Phase 2b clinical 54 CorVue ™ 54 Rebif ® 54 depsipeptide 54 Mycamine 54 bupropion SR 54 afamelanotide 54 O PPDS 54 fulvestrant 54 CCR5 antagonist 54 Aflibercept 54 therapeutic regimens 54 Zalypsis 54 norethindrone acetate 54 topical diclofenac 54 dacetuzumab 54 Advagraf 54 TKM ApoB 54 R roscovitine 54 convenient dosing regimen 54 MyVax R 54 adjuvant colon cancer 54 TASKi3 54 Alocrest 54 liposome formulation 54 Phase #/#a 54 PPAR gamma agonist 54 bevacizumab Avastin ® 54 oral probiotic 54 Corlux 54 BioVant 54 menadione 54 primary endpoint 54 mg doses 54 Vidofludimus 54 Onrigin 54 rivaroxaban 54 radezolid 54 gemcitabine Gemzar 54 QD dosing 54 multitargeted 54 acitretin 54 GVAX 54 REOLYSIN ® 54 talabostat 54 Omacetaxine mepesuccinate 54 multicenter Phase III 54 standard chemotherapy regimen 54 Calcitonin 54 factor Xa inhibitor 54 tadalafil Cialis 54 abacavir lamivudine 54 JANUVIA 54 neurologic progression 54 huN# DM1 54 plus prednisone 54 ziprasidone 54 bevacizumab Avastin Genentech 54 intracellular uptake 54 Aclidinium 54 caspofungin 54 Carvedilol 54 teratogenicity 54 Oxytrex 54 pegylated interferon alfa 54 levocetirizine 54 ustekinumab 54 dose escalation 54 fluconazole 54 secretin 54 Oral NKTR 54 VA# [002] 54 RE LY 54 conventional DMARDs 54 Pagoclone 54 RISPERDAL ® 54 paricalcitol 54 iroxanadine 54 liprotamase 54 potent antiviral 54 Aliskiren 54 Cleviprex TM clevidipine 54 masked placebo controlled 54 phase IIb study 54 ChronVac C R 53 OMNARIS HFA 53 HuMax CD4 53 docetaxel 53 VIR# 53 MORAb 53 DDP# 53 Darinaparsin 53 Augment Injectable 53 Factor VIIa 53 BoNTA 53 NEUGENE antisense 53 GOUT 53 multicenter Phase II 53 Numax 53 vascular disrupting agents 53 PD LID 53 Sym# 53 agomelatine 53 zotarolimus eluting stent 53 antidiabetic drugs 53 elvitegravir 53 antiepileptics 53 TREDAPTIVE 53 Bioavailability 53 celecoxib 53 liposomal amphotericin B 53 octreotide acetate 53 chemoradiotherapy 53 LEVADEX 53 Phase 2b clinical trials 53 Phase IIIb study 53 DXL# 53 rFIXFc 53 clopidogrel Plavix 53 potency 53 p# inhibitor 53 C2L 53 NasalFent 53 omega interferon 53 HQK 53 FTY# fingolimod 53 noninfectious uveitis 53 PF # [001] 53 PSMA ADC 53 tacrolimus ointment 53 proton pump inhibitor PPI 53 rALLy trial 53 galantamine 53 TAXUS TM 53 Vascugel ® 53 baminercept 53 GORE VIABAHN Endoprosthesis 53 genotoxicity 53 chemotherapeutic drug 53 randomized Phase 2b 53 prokinetic 53 Phase 2a 53 solithromycin 53 limiting toxicity DLT 53 APTIVUS R 53 Panzem R 53 Clonicel 53 pimecrolimus 53 preclinical 53 plus ribavirin 53 sitaxsentan 53 huC# DM4 53 TDF FTC 53 EGFR antibodies 53 eculizumab therapy 53 ACUROX ® 53 sustained virologic response 53 RAPAFLO R 53 RAPAFLO 53 Ereska 53 dose escalation clinical 53 trabectedin 53 evaluating tivozanib 53 refractory prostate cancer 53 lopinavir r 53 Noxafil 53 INVEGA ® 53 HMG CoA reductase inhibitors 53 IMC A# 53 doxorubicin docetaxel 53 Myocet 53 strontium ranelate 53 Tasimelteon 53 Excellarate 53 N acetylcysteine 53 ranolazine 53 PRTX 53 ATACAND 53 Neurodex 53 plasma kallikrein inhibitor 53 photoprotective drug 53 budesonide 53 neurotoxicity 53 leukotriene receptor antagonists 53 palifosfamide 53 pharmacokinetic pharmacodynamic PK PD 53 Prodarsan ® 53 cilengitide 53 roflumilast 53 Etoposide 53 ocular formulation 53 PROCHYMAL 53 IRESSA 53 prospectively defined 53 virological suppression 53 elotuzumab 53 ZACTIMA 53 selegiline 53 bavituximab 53 Platinol 53 alfa 2a 53 Sandostatin LAR 53 comparator arm 53 Taxol paclitaxel 53 Vaxfectin R 53 betamethasone dipropionate 53 oral antiplatelet 53 PEG INTRON 53 personalized immunotherapy 53 clinical pharmacology studies 53 multicenter clinical 53 reboxetine 53 Bendavia 53 MyVax 53 TNF inhibitor 53 olopatadine 53 ACZ# 53 BRIM2 53 Diovan HCT 53 VELCADE melphalan 53 milatuzumab 53 bronchodilatory 53 biologic therapy 53 Zelrix 53 Femara letrozole 53 peripherally acting 53 prospective randomized 53 Natalizumab 53 zileuton 53 double blind placebo 53 anti amnesic 53 Darusentan 53 brivaracetam 53 INCB# [002] 53 Civacir 53 NOXAFIL Oral Suspension 53 lumiliximab 53 bendamustine 53 intermittent dosing 53 nephrotoxicity 53 amifostine 53 administered intranasally 53 CERVARIX 53 convenient dosing regimens 53 sorafenib tablets 53 orally administered 53 cystinosis patients 53 Zenvia Phase III 53 therapeutic efficacy 53 noninferior 53 low dose cytarabine 53 Amplimexon 53 CTA# 53 Engerix B 53 Perforomist TM Inhalation Solution 53 TLR agonists 53 randomized controlled trial 53 APRISO 53 clinical 53 safinamide 53 Itopride 53 vernakalant hydrochloride 53 encapsulates siRNAs 53 miconazole 53 immunomodulatory therapy 53 intravenously administered 53 IFN Beta 53 FOLFOX 53 azacitidine 53 antiangiogenic therapy 53 Phase III clinical trials 53 mRCC 53 anti arrhythmic